Last updated on August 2019

A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Of The Efficacy and Safety of Apremilast (CC-10004) In Subjects With Mild To Moderate Plaque Psoriasis


Brief description of study

This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of apremilast (CC-10004) in subjects with mild to moderate plaque psoriasis.

Approximately 574 subjects with mild to moderate plaque psoriasis will be randomized 1:1 to receive either apremilast 30 mg BID or placebo for the first 16 weeks.

 

Clinical Study Identifier: TX227892

Find a site near you

Start Over